The COVID-19 pandemic is caused by the coronavirus SARS-CoV-2. Drugs for the treatment of this disease are urgently needed. The antiviral compound EIDD-2801 (also called molnupiravir or MK-4482, pictured) is a potential drug candidate against COVID-19 and is currently in phase II/III clinical trials. The drug has been repurposed—originally, it was designed as a ribonucleoside analogue inhibitor of influenza viruses.
Richard K. Plemper, Georgia State University, Atlanta, USA, and colleagues have found that EIDD-2801 can reduce the viral load in the upper respiratory tract and suppress virus transmission in ferrets. The team considers ferrets a good model because the animals can readily spread the virus, but generally do not develop severe disease—similar to young human adults. The team infected ferrets with SARS-CoV-2 and started treatment with EIDD-2801 when the animals began to shed virus from the nose. The infected, treated animals were co-housed with healthy, untreated ferrets in the same cage. None of these contact animals became infected. In a control experiment, all contacts of infected, untreated ferrets became infected.
In contrast to other possible COVID-19 treatments such as remdesivir or convalescent serum, EIDD-2801 can be given orally. This could significantly simplify treatment and transmission prevention. According to the researchers, the drug could possibly help to prevent widespread community transmission of COVID-19 until vaccinations are widely available.
Also of Interest
Article Views: 1053
Please note that to comment on an article you must be registered and logged in.
Registration is for free, you may already be registered to receive, e.g., the newsletter. When you register on this website, please ensure you view our terms and conditions. All comments are subject to moderation.